NASDAQ:GTHX G1 Therapeutics (GTHX) Stock Price, News & Analysis → A new way to collect income from stocks (From DTI) (Ad) Free GTHX Stock Alerts $4.28 +0.20 (+4.90%) (As of 04/17/2024 ET) Add Compare Share Share Today's Range$4.09▼$4.3550-Day Range$2.10▼$4.8852-Week Range$1.08▼$5.00Volume690,095 shsAverage Volume1.35 million shsMarket Capitalization$223.54 millionP/E RatioN/ADividend YieldN/APrice Target$9.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get G1 Therapeutics alerts: Email Address G1 Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside118.1% Upside$9.33 Price TargetShort InterestBearish5.28% of Shares Sold ShortDividend StrengthN/ASustainability-2.45Upright™ Environmental ScoreNews Sentiment1.15Based on 7 Articles This WeekInsider TradingSelling Shares$151,904 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.64) to ($0.26) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.59 out of 5 starsMedical Sector251st out of 914 stocksPharmaceutical Preparations Industry98th out of 404 stocks 3.3 Analyst's Opinion Consensus RatingG1 Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageG1 Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.28% of the outstanding shares of G1 Therapeutics have been sold short.Short Interest Ratio / Days to CoverG1 Therapeutics has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in G1 Therapeutics has recently increased by 2.60%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldG1 Therapeutics does not currently pay a dividend.Dividend GrowthG1 Therapeutics does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreG1 Therapeutics has received a 49.69% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Detoxifying agents for antineoplastic treatment (V03AF)" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for G1 Therapeutics is -2.45. Previous Next 3.4 News and Social Media Coverage News SentimentG1 Therapeutics has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for G1 Therapeutics this week, compared to 2 articles on an average week.Search Interest15 people have searched for GTHX on MarketBeat in the last 30 days. This is an increase of 36% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added G1 Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, G1 Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $151,904.00 in company stock.Percentage Held by InsidersOnly 8.23% of the stock of G1 Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 24.21% of the stock of G1 Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for G1 Therapeutics are expected to grow in the coming year, from ($0.64) to ($0.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of G1 Therapeutics is -4.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of G1 Therapeutics is -4.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioG1 Therapeutics has a P/B Ratio of 6.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressAI “wealth window” is closing soon!Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.I put together this personal video [HERE]… About G1 Therapeutics Stock (NASDAQ:GTHX)G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.Read More GTHX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GTHX Stock News HeadlinesMarch 21, 2024 | insidertrades.comG1 Therapeutics, Inc. (NASDAQ:GTHX) CFO Sells $19,771.94 in StockApril 17, 2024 | finance.yahoo.comG1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024April 17, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.April 17, 2024 | globenewswire.comG1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024April 14, 2024 | americanbankingnews.comG1 Therapeutics (NASDAQ:GTHX) Given Buy Rating at Needham & Company LLCApril 12, 2024 | markets.businessinsider.comBuy Rating for G1 Therapeutics: Market Position and Growth Potential Solidify Investment AppealApril 12, 2024 | markets.businessinsider.comBreaking Down G1 Therapeutics: 5 Analysts Share Their ViewsApril 7, 2024 | americanbankingnews.comHead-To-Head Survey: G1 Therapeutics (NASDAQ:GTHX) vs. Galmed Pharmaceuticals (NASDAQ:GLMD)April 17, 2024 | Priority Gold (Ad)Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.April 4, 2024 | globenewswire.comG1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceApril 1, 2024 | globenewswire.comG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 22, 2024 | marketwatch.comG1 Therapeutics Cuts Executive Salaries by 10% Amid Cost-Cutting MeasuresMarch 22, 2024 | seekingalpha.comWhy G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech LandscapeMarch 16, 2024 | finance.yahoo.comGTHX Apr 2024 3.000 callMarch 16, 2024 | finance.yahoo.comGTHX Apr 2024 3.500 putMarch 6, 2024 | finance.yahoo.comGTHX Mar 2024 3.000 putMarch 1, 2024 | globenewswire.comG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 1, 2024 | seekingalpha.comG1 Therapeutics, Inc. (GTHX) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | markets.businessinsider.comBuy Rating Justified by G1 Therapeutics’ Strong Q4 Earnings and Cosela’s Market TractionFebruary 29, 2024 | finance.yahoo.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | finance.yahoo.comQ4 2023 G1 Therapeutics Inc Earnings CallFebruary 28, 2024 | investing.comG1 Therapeutics Inc (GTHX)February 28, 2024 | finance.yahoo.comGTHX Jul 2024 2.500 putFebruary 28, 2024 | msn.comG1 Therapeutics GAAP EPS of -$0.21 beats by $0.07, revenue of $14.9M beats by $1.87MFebruary 28, 2024 | markets.businessinsider.comForecasting The Future: 5 Analyst Projections For G1 TherapeuticsFebruary 28, 2024 | finance.yahoo.comG1 Therapeutics Inc (GTHX) Reports Strong Revenue Growth in 2023February 28, 2024 | globenewswire.comG1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational HighlightsSee More Headlines Receive GTHX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/17/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GTHX CUSIPN/A CIK1560241 Webwww.g1therapeutics.com Phone(919) 213-9835Fax919-741-5830Employees100Year FoundedN/APrice Target and Rating Average Stock Price Target$9.33 High Stock Price Target$12.00 Low Stock Price Target$5.00 Potential Upside/Downside+118.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,970,000.00 Net Margins-58.13% Pretax Margin-54.36% Return on Equity-106.04% Return on Assets-33.99% Debt Debt-to-Equity Ratio1.46 Current Ratio3.87 Quick Ratio3.45 Sales & Book Value Annual Sales$82.51 million Price / Sales2.71 Cash FlowN/A Price / Cash FlowN/A Book Value$0.68 per share Price / Book6.29Miscellaneous Outstanding Shares52,230,000Free Float47,903,000Market Cap$223.54 million OptionableOptionable Beta1.73 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. John E. Bailey Jr. (Age 59)CEO, President & Director Comp: $1.06MMr. Mark Avagliano (Age 48)Chief Business Officer Comp: $628.54kMr. John W. Umstead V (Age 39)Chief Financial Officer Mr. Terry L. Murdock (Age 64)Chief Operating Officer Comp: $541.59kMr. William C. Roberts (Age 55)Vice President of Investor Relations & Corporate Communications Ms. Monica R. ThomasGeneral Counsel & Chief Compliance OfficerMr. Evan Hicks M.B.A.Vice President of MarketingDr. Rajesh K. Malik Ch.B. (Age 65)M.B., M.D., Chief Medical Officer Comp: $596.37kMr. Andrew Perry (Age 51)Chief Commercial Officer Comp: $568.6kMr. Jeff MacdonaldSenior Director of Investor Relations & Corporate CommunicationsMore ExecutivesKey CompetitorsAbeona TherapeuticsNASDAQ:ABEOSilverback TherapeuticsNASDAQ:SBTXGalectin TherapeuticsNASDAQ:GALTDesign TherapeuticsNASDAQ:DSGNGeneration BioNASDAQ:GBIOView All CompetitorsInsiders & InstitutionsJohn W V UmsteadSold 6,547 sharesTotal: $19,771.94 ($3.02/share)Vanguard Group Inc.Bought 31,605 shares on 3/11/2024Ownership: 3.796%Goldman Sachs Group Inc.Sold 4,829 shares on 3/1/2024Ownership: 0.022%Virtu Financial LLCBought 44,726 shares on 2/26/2024Ownership: 0.086%GSA Capital Partners LLPBought 6,651 shares on 2/16/2024Ownership: 0.050%View All Insider TransactionsView All Institutional Transactions GTHX Stock Analysis - Frequently Asked Questions Should I buy or sell G1 Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last twelve months. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GTHX shares. View GTHX analyst ratings or view top-rated stocks. What is G1 Therapeutics' stock price target for 2024? 4 Wall Street analysts have issued 1-year target prices for G1 Therapeutics' stock. Their GTHX share price targets range from $5.00 to $12.00. On average, they anticipate the company's stock price to reach $9.33 in the next year. This suggests a possible upside of 118.1% from the stock's current price. View analysts price targets for GTHX or view top-rated stocks among Wall Street analysts. How have GTHX shares performed in 2024? G1 Therapeutics' stock was trading at $3.05 on January 1st, 2024. Since then, GTHX shares have increased by 40.3% and is now trading at $4.28. View the best growth stocks for 2024 here. When is G1 Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our GTHX earnings forecast. How were G1 Therapeutics' earnings last quarter? G1 Therapeutics, Inc. (NASDAQ:GTHX) issued its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.06. The business had revenue of $14.87 million for the quarter, compared to the consensus estimate of $12.83 million. G1 Therapeutics had a negative trailing twelve-month return on equity of 106.04% and a negative net margin of 58.13%. During the same period last year, the business earned ($0.73) earnings per share. What other stocks do shareholders of G1 Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Kadmon (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE). When did G1 Therapeutics IPO? G1 Therapeutics (GTHX) raised $101 million in an initial public offering on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers. How do I buy shares of G1 Therapeutics? Shares of GTHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GTHX) was last updated on 4/17/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe “Perfect Storm” for GoldGold Safe ExchangeThe "Smart Money" Is Ready for May 1st Are You?Stansberry ResearchOptions trading has suddenly become more reliable.Eagle PublishingTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsYou won't believe what Citigroup just did to it's depositorsAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding G1 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.